SCHEMBL7843313

SCHEMBL7843313

CCOC(=O)C(Cc1ccc(OCCC=C2c3ccncc3-c3cnccc32)cc1)OC

nearest known ligand 0.48

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARG P37231 15/20 0.48
PPARA Q07869 15/20 0.47
PPARD Q03181 6/20 0.40
ACACB O00763 1/20 0.35
TBXAS1 P24557 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7852902 0.96 PPARG (0.48) PPARGPPARAPPARDACACB
SCHEMBL7843291 0.92 PPARG (0.55) PPARGPPARAPPARD
SCHEMBL7855305 0.91 PPARA (0.59) PPARGPPARAPPARD
SCHEMBL7965768 0.90 PPARA (0.53) PPARGPPARAPPARD
SCHEMBL7851304 0.89 PPARG (0.53) PPARGPPARAPPARD
SCHEMBL7854197 0.88 PPARG (0.55) PPARGPPARAPPARD
SCHEMBL7855547 0.88 PPARG (0.45) PPARGPPARAPPARD
SCHEMBL7855545 0.88 PPARG (0.45) PPARGPPARAPPARD
SCHEMBL6739563 0.87 PPARG (0.60) PPARGPPARAPPARD
SCHEMBL7851240 0.86 PPARA (0.53) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6300339-B1 USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE NOVO NORDISK A/S (DK) 2001-10-09 US claimed
EP-1123292-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP claimed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO claimed
US-6300339-B1 USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE NOVO NORDISK A/S (DK) 2001-10-09 US disclosed
EP-1123292-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP disclosed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed